The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Diabetes Technol Ther 9(4):317-26 (2007) PMID 17705687
Exenatide is an adjunctive therapy for type 2 diabetes, and preliminary evidence suggests that its glucoregulatory effects may be similar in the absence of oral therapy.
DOI: 10.1089/dia.2006.0024
Version: za2963e q8za6 q8zbf q8zc7 q8zd3 q8zeb q8zfa q8zg2